These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2992349)

  • 1. Reduced cholecystokinin levels in the limbic lobe in schizophrenia. A marker for pathology underlying the defect state?
    Ferrier IN; Crow TJ; Farmery SM; Roberts GW; Owen F; Adrian TE; Bloom SR
    Ann N Y Acad Sci; 1985; 448():495-506. PubMed ID: 2992349
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia.
    Ferrier IN; Roberts GW; Crow TJ; Johnstone EC; Owens DG; Lee YC; O'Shaughnessy D; Adrian TE; Polak JM; Bloom SR
    Life Sci; 1983 Aug; 33(5):475-82. PubMed ID: 6135969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides, the limbic lobe and schizophrenia.
    Roberts GW; Ferrier IN; Lee Y; Crow TJ; Johnstone EC; Owens DG; Bacarese-Hamilton AJ; McGregor G; O'Shaughnessey D; Polak JM
    Brain Res; 1983 Dec; 288(1-2):199-211. PubMed ID: 6198024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin in the retina of vertebrates.
    Osborne NN
    Ann N Y Acad Sci; 1985; 448():157-66. PubMed ID: 2992343
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholecystokinin and cultured spinal neurons. Immunohistochemistry, receptor binding, and neurophysiology.
    Rogawski MA; Beinfeld MC; Hays SE; Hökfelt T; Skirboll LR
    Ann N Y Acad Sci; 1985; 448():403-12. PubMed ID: 2992347
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmortem studies in psychiatry.
    Bracha HS; Kleinman JE
    Psychiatr Clin North Am; 1984 Sep; 7(3):473-85. PubMed ID: 6384958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biochemical analysis of neurotransmitters in temporal lobe and limbic system of post-mortem brains from schizophrenic patients].
    Toru M; Shibuya H; Mitsushio H; Noda K; Takashima M; Mataga N; Ogawa A; Watanabe S; Ichikawa H
    Seishin Shinkeigaku Zasshi; 1984; 86(10):827-40. PubMed ID: 6151711
    [No Abstract]   [Full Text] [Related]  

  • 8. [Localization and role of cholecystokinin and its receptors in the functional organization of the basal ganglia].
    Schiffmann S
    Bull Mem Acad R Med Belg; 1993; 148(10):370-9. PubMed ID: 7987278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine receptors, limbic pathology and schizophrenia.
    Joyce JN
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():502A-503A. PubMed ID: 1323403
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dopamine hypothesis in schizophrenia--recent findings in limbic system abnormality].
    Toru M; Watanabe S; Kaneno S
    Nihon Rinsho; 1978; 36(1):76-82. PubMed ID: 24768
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholecystokinin-dopamine receptor interactions as studied with cholecystokinin receptor antagonists.
    Murphy RB
    Prog Clin Biol Res; 1985; 192():105-13. PubMed ID: 3001746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of cholecystokinin mRNA in dopamine cells in the ventral mesencephalon of a human with schizophrenia.
    Schalling M; Friberg K; Bird E; Goldstein M; Schiffmann S; Mailleux P; Vanderhaeghen JJ; Hökfelt T
    Acta Physiol Scand; 1989 Nov; 137(3):467-8. PubMed ID: 2688364
    [No Abstract]   [Full Text] [Related]  

  • 13. Postnatal ontogeny of cholecystokinin receptors in rat brain.
    Hays SE; Houston SH; Beinfeld MC; Paul SM
    Brain Res; 1981 May; 213(1):237-41. PubMed ID: 6263413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.
    Bird ED; Spokes EG; Iversen LL
    Brain; 1979 Jun; 102(2):347-60. PubMed ID: 455044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-phase radioimmune assay. Using 3 H-labeled antigen for the mouse olfactory bulb specific protein.
    Margolis FL
    Anal Biochem; 1972 Dec; 50(2):602-7. PubMed ID: 4118997
    [No Abstract]   [Full Text] [Related]  

  • 16. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides.
    Hökfelt T; Skirboll L; Everitt B; Meister B; Brownstein M; Jacobs T; Faden A; Kuga S; Goldstein M; Markstein R
    Ann N Y Acad Sci; 1985; 448():255-74. PubMed ID: 2411182
    [No Abstract]   [Full Text] [Related]  

  • 17. Localization of cholecystokinin receptors on neuronal elements in rat caudate nucleus.
    Hays SE; Meyer DK; Paul SM
    Brain Res; 1981 Aug; 219(1):208-13. PubMed ID: 6266600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications.
    Constantinidis J; Bouras C; Richard J
    Clin Neuropathol; 1983; 2(2):47-54. PubMed ID: 6189657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine in schizophrenia.
    Heritch AJ
    Am J Psychiatry; 1992 Nov; 149(11):1620-1. PubMed ID: 1415847
    [No Abstract]   [Full Text] [Related]  

  • 20. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay.
    Beinfeld MC; Meyer DK; Eskay RL; Jensen RT; Brownstein MJ
    Brain Res; 1981 May; 212(1):51-7. PubMed ID: 7225864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.